Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial

A Randomized Controlled Trial of Renin-Angiotensin-Aldosterone System Inhibitor Management in Patients Admitted in Hospital with COVID-19

(2022) Abhinav Sharma et al.   AMERICAN HEART JOURNAL

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial

(2022) J. M. McGree et al.   Trials

Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury

(2022) Michael A. Puskarich et al.   JAMA Network Open

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19

(2021) Renato D. Lopes et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

(2021) Jordana B Cohen et al.   Lancet Respiratory Medicine

Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system

(2021) Man Lung Yeung et al.   CELL

Comparison of losartan and amlodipine effects on the outcomes of patient with COVID‐19 and primary hypertension: A randomised clinical trial

(2021) Masoud Nouri‐Vaskeh et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform

(2021) Rohini Mathur et al.   LANCET

Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia

(2021) Matthew Geriak et al.   Infectious Diseases and Therapy

Estimating age-specific COVID-19 fatality risk and time to death by comparing population diagnosis and death patterns: Australian data

(2021) Ian C. Marschner   BMC Medical Research Methodology

Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial

(2021) Carinna Hockham et al.   Trials

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

(2021) Axel Bauer et al.   Lancet Respiratory Medicine

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

(2020) Jun Lan et al.   NATURE

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

(2020) Annemarie B Docherty et al.   BMJ-British Medical Journal

A minimal common outcome measure set for COVID-19 clinical research

(2020) John C Marshall et al.   LANCET INFECTIOUS DISEASES

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment

(2020) Anant Parasher   POSTGRADUATE MEDICAL JOURNAL

A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy

(2012) et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION